-

AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Wednesday, December 2, 2026 at 8:20am ET and members of management will be available for 1x1 meetings.

A webcast of the fireside chat can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from its boron chemistry platform. For more information please visit our website at www.an2therapeutics.com.

Contacts

COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com

AN2 Therapeutics, Inc.

NASDAQ:ANTX

Release Versions

Contacts

COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com

More News From AN2 Therapeutics, Inc.

AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2026 and recent business and scientific highlights. “The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportuni...

AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 9:30 am GMT and members of management will be available for 1x1 meetings.A webcast of the presentation can be accessed...

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the advancement of AN2-504661, a novel boron-based ENPP1 inhibitor, as a development candidate for the treatment of HPP. AN2-504661 was selected following extensive lead optimization and preclinical evaluation demonstrating the potential for a differentiated p...
Back to Newsroom